Please login to the form below

Ozurdex

This page shows the latest Ozurdex news and features for those working in and with pharma, biotech and healthcare.

NICE backs Bayer's Eylea in diabetic eye condition

TheInstitute also recommends Allergan's Ozurdex in final guidance. Bayer's Eylea and Allergan's Ozurdex have been recommended for use on the NHS in England to treat diabetic macular oedema ... Meanwhile, NICE also recommended the use of Allergan's

Latest news

NICE recommends Ozurdex for diabetic eye condition

The preliminary recommendations cite the implant, marketed by Allergan as Ozurdex, as a treatment option in patients where the implant is to be used in an eye with an intraocular (pseudophakic) ... Ozurdex is injected into the eye once every six months
Fresh approval for Roche's Lucentis as competition heats up

Roche's drug is being challenged in the market by Bayer's Eylea (aflibercept) as well as newer entrants such as Allergan's Ozurdex (intravitreal dexamethasone).
New eye indication for Allergan’s Ozurdex

The European Commission granted marketing authorisation to Ozurdex, an eye implant that contains the corticosteroid dexamethasone, as a treatment for adults with visual impairment due to diabetic macular oedema (DMO). ... Ozurdex joins a competitive
Allergan will start phase III DARPin trials next year

On the plus side, Allergan said the FDA had approved a new indication for its intravitreal implant Ozurdex (dexamethasone), namely the treatment of diabetic macular oedema (DME) in adults who have
NICE against new indication for Novartis' Lucentis

Its draft guidance concluded the ICER for Lucentis in central RVO versus Allergan's Ozurdex (dexamethasone) intravitreal implant, the currently approved treatment, was likely to be over £37, 400 per QALY ... Ozurdex was recommended by NICE earlier this

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

Allergan and taking a specialised approach

spasticity associated with stroke and for the ophthalmology treatment Ozurdex in diabetic macular oedema.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Vice President: Competitive Salary Offered

Director of Scientific Services, Medical Communications, Six fig...: Six figure salary

Account Manager– Medical Communications: (Negotiable - depending on experience)

Principal Medical Writer: £48 - 58, 000 according to skills and experience benefits

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Account Director or Senior Account Director: Salary TBC

Consultant: competitive salary

Senior Medical Writer, MedComms Agency: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

How do companies prepare for reimbursement?: Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
Integrating electronic health records into clinical trials: How organisations are working to realise the research potential of EHRs...
Keeping up the fight against HIV and using the lessons to tackle other threats: Danny Buckland interviews Gilead’s Mike Elliott...